A retrospective study of serum KL-6 levels during treatment with biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients: A report from the Ad Hoc Committee for Safety of Biological DMARDs of the Japan College of Rheumatology

Modern Rheumatology

Volumn 23, Issue 2, 2013, Pages 297-303

  Takamura, Akito ^a   Hirata, Shintaro ^b   Nagasawa, Hayato ^c   Kameda, Hideto ^d   Seto, Yohei ^e   Atsumi, Tatsuya ^f   Dohi, Makoto ^g   Koike, Takao ^h   Miyasaka, Nobuyuki ^a   Harigai, Masayoshi ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

^d Medical Research Division   (Japan)

^e TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^f HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g UNIVERSITY OF TOKYO   (Japan)

^h NTT CORPORATION   (Japan)

Author keywords

Biological disease modifying antirheumatic drug; KL 6; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; METHOTREXATE; MUC1 PROTEIN, HUMAN; MUCIN 1;

ADULT; AGED; ARTICLE; BLOOD; DRUG COMBINATION; FEMALE; HUMAN; JAPAN; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; JAPAN; MALE; METHOTREXATE; MIDDLE AGED; MUCIN-1; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84883197280     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-012-0658-1     Document Type: Article

References (20)

1. Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67: 189-94.
2. Koike T, Harigai M, Inokuma S, Inoue K, Ishiguro N, Ryu J, et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol. 2009;36: 898-906.
3. Koike T, Harigai M, Ishiguro N, Inokuma S, Takei S, Takeuchi T, et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3, 000 patients. Mod Rheumatol Japan Rheum Assoc. 2011.
4. Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, et al. Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. Ann Rheum Dis. 2011;70: 2148-51.
5. Koike R, Takeuchi T, Eguchi K, Miyasaka N. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol. 2007;17: 451-8.
6. Koike R, Harigai M, Atsumi T, Amano K, Kawai S, Saito K, et al. Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. Mod Rheumatol. 2009;19: 351-7.
7. Japan College of Rheumatology. Guideline for the use of TNF inhibitors in rheumatoid arthritis, Japan College of Rheumatology. Tokyo 2010 (in Japanese). http://www.ryumachi-jp.com/ info/guideline-TNF-100930.html (updated 30-09-2010; cited 01-11-2011).
8. Japan College of Rheumatology. Guideline for the use tocilizumab in rheumatoid arthritis, Japan College of Rheumatology (in Japanese). 2010. http://www.ryumachi-jp.com/info/guideline- TCZ-100716.html (updated 16-07-2010).
9. Stahel RA, Gilks WR, Lehmann HP, Schenker T. Third International Workshop on Lung Tumor and Differentiation Antigens: overview of the results of the central data analysis. Int J Cancer Suppl. 1994;8: 6-26.
10. Kohno N, Awaya Y, Oyama T, Yamakido M, Akiyama M, Inoue Y, et al. KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease. Am Rev Respir Dis. 1993;148: 637-42.
11. Miyata M, Sakuma F, Fukaya E, Kobayashi H, Rai T, Saito H, et al. Detection and monitoring of methotrexate-associated lung injury using serum markers KL-6 and SP-D in rheumatoid arthritis. Intern Med. 2002;41: 467-73.
12. Nakajima H, Harigai M, Hara M, Hakoda M, Tokuda H, Sakai F, et al. KL-6 as a novel serum marker for interstitial pneumonia associated with collagen diseases. J Rheumatol. 2000;27: 1164-70.
13. Nakamura H, Tateyama M, Tasato D, Haranaga S, Yara S, Higa F, et al. Clinical utility of serum beta-D-glucan and KL-6 levels in Pneumocystis jirovecii pneumonia. Intern Med. 2009;48: 195-202.
14. Ohnishi H, Yokoyama A, Yasuhara Y, Watanabe A, Naka T, Hamada H, et al. Circulating KL-6 levels in patients with drug induced pneumonitis. Thorax. 2003;58: 872-5.
15. Tasaka S, Hasegawa N, Kobayashi S, Yamada W, Nishimura T, Takeuchi T, et al. Serum indicators for the diagnosis of pneumocystis pneumonia. Chest. 2007;131: 1173-80.
16. Takeuchi T, Miyasaka N, Inoue K, Abe T, Koike T. Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. Mod Rheumatol Japan Rheum Assoc. 2009;19: 478-87.
17. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31: 315-24.
18. Harigai M, Takamura A, Atsumi T, Dohi M, Hirata S, Kameda H, et al. Elevation of KL-6 serum levels in clinical trials of tumor necrosis factor inhibitors in patients with rheumatoid arthritis-a report from the ad-hoc committee for safety of biological DAMRDs of the Japan College of Rheumatology. 2012 (submitted).
19. van den Blink B, Wijsenbeek MS, Hoogsteden HC. Serum biomarkers in idiopathic pulmonary fibrosis. Pulm Pharmacol Ther. 2010;23: 515-20.
20. Oyama T, Kohno N, Yokoyama A, Hirasawa Y, Hiwada K, Oyama H, et al. Detection of interstitial pneumonitis in patients with rheumatoid arthritis by measuring circulating levels of KL- 6, a human MUC1 mucin. Lung. 1997;175: 379-85.